The World Health Organization announced Wednesday the resumption of clinical trials on hydroxychloroquine, nine days after having suspended them following the publication of a study in the prestigious medical journal The Lancet.
At the end of April, the World Health Organization launched clinical trials, notably on hydroxychloroquine, called "Solidarity", with the aim of finding an effective treatment for Covid-19.
PODCAST. Who is Didier Raoult, French cantor of chloroquine
On May 25, the world health authority announced the suspension of trials on hydroxychloroquine following the publication of a study in the medical journal The Lancet deeming ineffective or even harmful the use of chloroquine or its derivatives as hydroxychloroquine against Covid-19.
VIDEO. For safety, WHO suspends clinical trials with hydroxychloroquine
The suspension of the trials was to allow WHO to analyze the information available, and a decision was expected in mid-June. But as The Lancet distanced itself from the study on Tuesday evening, admitting in a formal warning that "important questions" hovered over it, the WHO published its findings sooner than expected.
"Confident"
"We are now fairly confident that we have not seen any differences in mortality," Soumya Swaminathan, WHO chief scientist, said on Wednesday during a virtual press conference from the headquarters of the organization in Geneva.
Newsletter - The essentials of the news
Every morning, the news seen by Le ParisienI'm registering
Your email address is collected by Le Parisien to allow you to receive our news and commercial offers. Find out more
After analyzing "available data on mortality", the members of the Safety and Monitoring Committee considered "that there is no reason to modify the protocol" of clinical trials, according to the Director-General of WHO, Tedros Adhanom Ghebreyesus.